http://www.fda.gov/bbs/topics/ANSWERS/ANS01010.html
U.S. Food and Drug Administration
FDA has approved Zyvox (linezolid), the first antibacterial drug in a new class to treat infections associated with vancomycin-resistant Enterococcus faecium (VREF), including cases with bloodstream infection. Zyvox also received approval for treatment of hospital-acquired pneumonia and complicated skin and skin structure infections, including cases due to methicillin-resistant Staphylococcus aureus (MRSA). In addition, approval was granted for treatment of community-acquired pneumonia and uncomplicated skin and skin structure infections.